Can-Fite BioPharma Ltd. (CANF) Income Statement
CANF 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCANF revenue and net income
Where CANF's revenue goes
2025Each bar shows an amount and its share of revenue. CANF kept −2,426.7% of revenue as net income.
CANF profit margins
CANF growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −39.4% | −20.4% | −11.8% | +9.5% |
| Gross profit | −43.0% | −22.0% | −12.8% | +8.8% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CANF quarterly EPS vs estimates
Can-Fite BioPharma beat the analyst EPS estimate in 3 of the last 4 quarters.
CANF income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $408,212 | $674,000 | $743,000 | $810,000 | $853,000 | $763,000 | $2.0M | $3.8M | $844,746 | $169,500 |
| Cost of revenue | $24,190 | $7,033 | $14,999 | $0 | $0 | $0 | $51,000 | $87,000 | −$2,254 | −$500 |
| Gross profit | $384,022 | $674,000 | $743,000 | $810,000 | $853,000 | $763,000 | $2.0M | $3.8M | $844,746 | $169,500 |
| Research & development | $6.7M | $5.8M | $6.0M | $7.8M | $9.8M | $12.0M | $11.0M | $6.1M | $5.3M | $6.1M |
| Sales, general & admin | $3.7M | $3.0M | $3.0M | $3.1M | $3.8M | $3.0M | $3.1M | $3.2M | $2.9M | $2.7M |
| Total operating expenses | $10.4M | $8.8M | $8.9M | $10.9M | $13.7M | $14.9M | $14.0M | $9.2M | $8.2M | $8.8M |
| Operating income | −$10.0M | −$8.1M | −$8.2M | −$10.1M | −$12.8M | −$14.1M | −$12.0M | −$5.4M | −$7.4M | −$8.6M |
| Interest income | $284,000 | $291,000 | $506,000 | $222,000 | $24,000 | $44,000 | $72,000 | $51,000 | $71,642 | $88,910 |
| Interest expense | $14,111 | $14,000 | $14,000 | $63,000 | $227,000 | $363,000 | $427,000 | $1.2M | $1.1M | $27,296 |
| Income before taxes | −$9.9M | −$7.9M | −$7.6M | −$10.2M | −$12.6M | −$14.4M | −$12.6M | −$6.6M | −$5.0M | −$7.0M |
| Income taxes | — | — | $1 | $63,000 | −$20,000 | $363,000 | $427,000 | $4,000 | $29,922 | $29,116 |
| Net income | −$9.9M | −$7.9M | −$7.6M | −$10.2M | −$12.6M | −$14.4M | −$12.6M | −$6.6M | −$5.0M | −$6.9M |
| EBITDA | −$10.0M | −$8.1M | −$8.2M | −$10.1M | −$12.8M | −$14.1M | −$12.0M | −$6.1M | −$7.2M | −$8.7M |
| EPS (diluted) | −$0.03 | −$0.01 | −$61.51 | −$62.81 | −$124.20 | −$290.78 | −$660.44 | −$482.91 | −$430.50 | −$571.05 |
| Gross margin | 94.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −2,456.8% | −1,206.2% | −1,103.0% | −1,246.4% | −1,505.5% | −1,853.1% | −590.9% | −141.7% | −873.1% | −5,093.7% |
| Net margin | −2,426.7% | −1,169.1% | −1,027.5% | −1,263.7% | −1,476.6% | −1,892.9% | −621.3% | −172.0% | −588.2% | −4,069.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $101,000 | $101,000 | $101,500 | $101,500 | $101,000 | $101,000 | $179,000 | $179,000 | $158,000 | $158,000 | $155,000 | $196,000 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $101,000 | $101,000 | $101,500 | $101,500 | $101,000 | $101,000 | $179,000 | $179,000 | $158,000 | $158,000 | $155,000 | $196,000 |
| Research & development | $1.7M | $1.7M | $1.8M | $1.8M | $1.5M | $1.5M | $1.4M | $1.4M | $1.4M | $1.4M | $1.3M | $1.3M |
| Sales, general & admin | $713,000 | $713,000 | $798,000 | $798,000 | $1.0M | $1.0M | $761,000 | $761,000 | $762,500 | $762,500 | $722,000 | $762,000 |
| Total operating expenses | $2.4M | $2.4M | $2.6M | $2.6M | $2.5M | $2.5M | $2.2M | $2.2M | $2.2M | $2.2M | $2.0M | $2.1M |
| Operating income | −$2.3M | −$2.3M | −$2.5M | −$2.5M | −$2.4M | −$2.4M | −$2.0M | −$2.0M | −$2.0M | −$2.0M | −$1.8M | −$1.9M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $14,000 | $3,000 |
| Income before taxes | −$2.3M | −$2.3M | −$2.5M | −$2.5M | −$2.4M | −$2.4M | −$2.0M | −$2.0M | −$2.0M | −$2.0M | −$1.7M | −$1.8M |
| Income taxes | — | — | — | — | — | — | — | — | — | — | −$3,750 | −$3,500 |
| Net income | −$2.3M | −$2.3M | −$2.5M | −$2.5M | −$2.4M | −$2.4M | −$2.0M | −$2.0M | −$2.0M | −$2.0M | −$1.7M | −$1.8M |
| EBITDA | −$2.3M | −$2.3M | −$2.5M | −$2.5M | −$2.4M | −$2.4M | −$2.0M | −$2.0M | −$2.0M | −$2.0M | −$1.8M | −$1.9M |
| EPS (diluted) | — | — | — | — | $0.00 | $0.00 | — | — | — | — | −$60.00 | −$0.44 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −2,316.8% | −2,316.8% | −2,488.7% | −2,488.7% | −2,424.8% | −2,424.8% | −1,127.4% | −1,127.4% | −1,295.6% | −1,295.6% | −1,183.2% | −951.5% |
| Net margin | −2,277.7% | −2,277.7% | −2,439.4% | −2,439.4% | −2,413.9% | −2,413.9% | −1,095.8% | −1,095.8% | −1,252.2% | −1,252.2% | −1,065.8% | −899.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CANF's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CANF financial results
In fiscal year 2025 (ended December 31, 2025), Can-Fite BioPharma reported revenue of $0.4 million, down 39.4% from the year before. It had a net loss of $9.9 million, a net profit margin of −2,426.7%. Diluted earnings per share came to −$0.03. Over five years revenue grew at an average rate of −11.8% a year.
See the CANF stock overview for the latest quote and news, or the CANF chart for price history and technical indicators.
CANF income statement FAQ
What is Can-Fite BioPharma's annual revenue?
Can-Fite BioPharma reported total revenue of $0.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 39.4% from $0.7 million the previous year.
Is Can-Fite BioPharma profitable?
No. Can-Fite BioPharma reported a net loss of $9.9 million in fiscal 2025, a net profit margin of −2,426.7%; its operating margin was −2,456.8%.
What is Can-Fite BioPharma's gross margin?
Can-Fite BioPharma's gross margin was 94.1% in fiscal 2025: for every $100 of revenue, Can-Fite BioPharma kept $94 after the direct cost of its products and services.
How much does Can-Fite BioPharma spend on research and development?
Can-Fite BioPharma spent $6.7 million on research and development in fiscal 2025, 1,652.6% of revenue.
How fast is Can-Fite BioPharma growing?
Revenue grew −11.8% a year on average over the last five fiscal years, from $0.8 million to $0.4 million.
What are Can-Fite BioPharma's earnings per share?
Can-Fite BioPharma earned $-0.03 per diluted share in fiscal 2025, compared with $-0.01 a year earlier.
When does Can-Fite BioPharma's fiscal year end?
Can-Fite BioPharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.